Imunon (IMNN) investor relations material

Executive summary

• Entered 2026 with strong momentum after a transformational 2025, advancing IMNN-001 immunotherapy for frontline ovarian cancer, with Phase III OVATION 3 trial enrollment ahead of plan and strong investigator and medical community interest.

• Phase II OVATION 2 study showed unprecedented median overall survival benefit, increasing from 11.1 months (July 2024) to 14.7 months in final review; PARP inhibitor subgroup saw a 24.2-month benefit (65.6 vs. 41.4 months).

• Robust clinical and translational data presented at major scientific forums, fueling enthusiasm and accelerating site activation and enrollment.

• Strategic reorganization implemented in February 2026 to reduce non-essential costs and focus on OVATION 3.

Financial highlights

• Cash and cash equivalents were $8.8 million as of December 31, 2025, up from $5.9 million at year-end 2024, reflecting disciplined cash management and proceeds from warrant exercises, ATM usage, and a $7.0 million direct offering.

• Research and development expenses for 2025 were $7.8 million, significantly lower year-over-year due to completion of OVATION 2 and focus on OVATION 3.

• General and administrative expenses declined 8% year-over-year through streamlined operations, totaling $6.9 million in 2025.

• Net loss for 2025 was $14.5 million ($6.83 per share), improved from $18.6 million ($16.94 per share) in 2024.

• Net cash used for operating activities was $13.9 million in 2025, down from $18.9 million in 2024.

Outlook and guidance

• Targeting enrollment of 80 patients in OVATION 3 within 12 months and full enrollment by 2029, with interim analyses for early efficacy stopping rules planned.

• Focused on securing long-term, non-dilutive financing, expanding institutional investor base, and pursuing strategic partnerships for PlaCCine DNA vaccine technology.

• Strategic reorganization expected to further reduce operating expenses while supporting clinical development priorities.